The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
Friedrich MJ, et al.
April 2023
Authors and Affiliates
Mirco J Friedrich 1 , Paola Neri 2 , Niklas Kehl 3 , Julius Michel 3 , Simon Steiger 4 , Michael Kilian 3 , Noémie Leblay 5 , Ranjan Maity 5 , Roman Sankowski 6 , Holly Lee 2 , Elie Barakat 5 , Sungwoo Ahn 5 , Niels Weinhold 7 , Karsten Rippe 8 , Lukas Bunse 3 , Michael Platten 9 , Hartmut Goldschmidt 10 , Carsten Müller-Tidow 10 , Marc-Steffen Raab 11 , Nizar J Bahlis 12;
1 Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: mfriedri@broadinstitute.org.
2 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada.
3 Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
4 Division of Chromatin Networks, BioQuant Center & German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
5 Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada.
6 Department of Neuropathology, Freiburg University Hospital, Freiburg, Germany.
7 Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
8 Division of Chromatin Networks, BioQuant Center & German Cancer Research Center (DKFZ), Heidelberg, Germany.
9 Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany;
Helmholtz Institute of Translational Oncology (HI-TRON), Mainz, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim Germany.
10 Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
11 Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic
address: marc.raab@med.uni-heidelberg.de.
12 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada. Electronic address: nbahlis@ucalgary.ca.